$JAGX FORM 8-K On July 19, 2022, Napo Pharmaceuticals, Inc. (“Napo Pharma”), the wholly-owned subsidiary of Jaguar Health, Inc. (“Jaguar”), entered into an amended and restated license agreement (the “Amended License Agreement”) with Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.